OBI Pharma - Asset Resilience Ratio

Latest as of December 2025: 12.48%

OBI Pharma (4174) has an Asset Resilience Ratio of 12.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

NT$427.00 Million

≈ $13.45 Million USD Cash + Short-term Investments

Total Assets

NT$3.42 Billion

≈ $107.79 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how OBI Pharma's Asset Resilience Ratio has changed over time. Check OBI Pharma (4174) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down OBI Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OBI Pharma stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$427.00 Million	12.48%
Total Liquid Assets	NT$427.00 Million	12.48%

Asset Resilience Insights

Moderate Liquidity: OBI Pharma has 12.48% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

OBI Pharma Industry Peers by Asset Resilience Ratio

Compare OBI Pharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
ALTEOGEN Inc KQ:196170	Biotechnology	55.57%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	34.94%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Inventiva S.A PA:IVA	Biotechnology	52.73%

Annual Asset Resilience Ratio for OBI Pharma (2011–2025)

The table below shows the annual Asset Resilience Ratio data for OBI Pharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	12.48%	NT$427.00 Million ≈ $13.45 Million	NT$3.42 Billion ≈ $107.79 Million	-12.26pp
2024-12-31	24.74%	NT$1.40 Billion ≈ $44.07 Million	NT$5.65 Billion ≈ $178.12 Million	-8.86pp
2023-12-31	33.60%	NT$1.88 Billion ≈ $59.33 Million	NT$5.60 Billion ≈ $176.55 Million	+33.13pp
2022-12-31	0.47%	NT$31.46 Million ≈ $991.23K	NT$6.63 Billion ≈ $209.00 Million	-2.69pp
2021-12-31	3.16%	NT$141.77 Million ≈ $4.47 Million	NT$4.49 Billion ≈ $141.36 Million	-4.02pp
2020-12-31	7.18%	NT$383.53 Million ≈ $12.08 Million	NT$5.34 Billion ≈ $168.23 Million	+7.16pp
2019-12-31	0.02%	NT$1.39 Million ≈ $43.92K	NT$5.66 Billion ≈ $178.42 Million	-38.95pp
2017-12-31	38.97%	NT$2.02 Billion ≈ $63.72 Million	NT$5.19 Billion ≈ $163.51 Million	+1.68pp
2016-12-31	37.29%	NT$2.36 Billion ≈ $74.34 Million	NT$6.33 Billion ≈ $199.37 Million	+4.71pp
2012-12-31	32.58%	NT$284.81 Million ≈ $8.97 Million	NT$874.17 Million ≈ $27.54 Million	-41.39pp
2011-12-31	73.97%	NT$386.65 Million ≈ $12.18 Million	NT$522.72 Million ≈ $16.47 Million	--

pp = percentage points

About OBI Pharma

TWO:4174 Taiwan Biotechnology

Market Cap

$104.05 Million

NT$3.30 Billion TWD

Market Cap Rank

#18987 Global

#1032 in Taiwan

Share Price

NT$25.10

Change (1 day)

+0.80%

52-Week Range

NT$23.25 - NT$50.50

All Time High

NT$743.00